Rocket Pharmaceuticals (RCKT) Earnings Date & Reports

Key Takeaways

• Rocket Pharmaceuticals (NASDAQ: RCKT) is expected to report Q3 2026 results around early November 2026, with a consensus loss estimate of -$0.39 per share.
• Revenue expectations remain negligible — roughly $0.2 million — reflecting the company's early-commercial, largely pre-revenue stage.
• The prior-year comparison is a net loss of -$0.45 per share in Q3 2025, making the year-over-year loss trend a key focus.
• Investor attention centers on the FDA-aligned pivotal Phase 2 trial of RP-A501 for Danon disease, the company's lead cardiovascular gene therapy program.
• A recently secured $150 million credit facility from Hercules Capital strengthens the balance sheet and supports the clinical pipeline.
• Rocket has beaten consensus earnings-per-share (EPS) estimates in six of its last eight quarters, though most of these were loss-per-share beats.
• For more on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages.
• Discover Trending AI Robots for data-driven trading ideas across the market.

Earnings Context and Why It Matters

Rocket Pharmaceuticals is a commercial-stage biotechnology company advancing gene therapies for rare, life-threatening diseases, with a strategic focus on inherited cardiovascular disorders. Its pipeline is anchored by RP-A501, an adeno-associated virus (AAV) gene therapy in a pivotal Phase 2 trial for Danon disease. Because the company generates little to no product revenue, the quarterly earnings release matters less for top-line results and more for clinical progress, cash runway, and spending discipline. Investors closely track research and development (R&D) expense trends, restructuring savings, and management commentary on regulatory milestones. Following a strategic reorganization that cut operating expenses by roughly 25%, this report will signal whether the leaner cost structure is holding while the pivotal Danon disease program advances toward key data and potential regulatory milestones.

Earnings Expectations

Analysts expect Rocket Pharmaceuticals to report a net loss of approximately -$0.39 per share for the third quarter of 2026, compared with a loss of -$0.45 per share in the same period a year earlier. Consensus revenue is minimal at around $0.2 million, consistent with a company that has not yet achieved meaningful commercial sales. These figures should be viewed with caution, however: the prior quarter (Q2 2026) produced a headline EPS of $1.08 that was driven by a large one-time item rather than operating income, underscoring how non-operating gains can distort quarter-to-quarter comparisons. Investors will focus instead on core operating loss, R&D spending, and cash balances. Rocket has beaten consensus EPS in six of the past eight quarters, though historically these have been loss-per-share beats with limited top-line impact.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for investors tracking biotechnology names like Rocket Pharmaceuticals alongside the broader healthcare sector. Explore the AI Screener to streamline your market research.

Market Reaction and Investor Sentiment

Sentiment heading into Rocket Pharmaceuticals' Q3 2026 report has been mixed but cautiously improving. The stock has traded in a low single-digit range, reflecting the market's wait-and-see posture on the Danon disease program. On the positive side, the company secured FDA alignment in September 2026 on the path to complete the pivotal Phase 2 trial of RP-A501, a milestone that triggered several analyst actions, including upgrades from Needham and Goldman Sachs and reaffirmed Outperform-style ratings from firms such as Cantor Fitzgerald. Conversely, the shares carry elevated risk because the pivotal trial remains ongoing and the company is not yet generating material revenue. Key risk factors heading into the print include any unexpected increase in R&D expenses, dilution from financing activity, or delays in clinical enrollment and dosing under the modified protocol.

Forward Outlook and Key Factors to Monitor

Following the Q3 2026 report, investors should watch the Danon disease program most closely. The company has aligned with the FDA on a 12-patient pivotal efficacy population and 12-month co-primary endpoints for RP-A501, and the pace of enrollment and dosing will be a central narrative. Any updated safety or efficacy signals from the pivotal trial, or from longer-term Phase 1 follow-up, could materially shift sentiment.

Cash runway is the second key factor. As of late 2025, Rocket estimated its resources could fund operations into the second quarter of 2027, and the new $150 million credit facility from Hercules Capital — with an initial $35 million tranche — provides additional flexibility. Investors will want to see that spending remains disciplined while the company funds its lead cardiovascular programs.

Finally, monitor the broader pipeline. Rocket has de-prioritized its Fanconi Anemia and Pyruvate Kinase Deficiency programs to concentrate resources on its AAV cardiovascular platform, including RP-A601 for PKP2-ACM (a heart muscle condition) and RP-A701 for BAG3-DCM (dilated cardiomyopathy). The lentiviral candidate KRESLADI for severe leukocyte adhesion deficiency-I (LAD-I) also remains in play following a Biologics License Application (BLA) resubmission. Progress on any of these fronts, combined with stable cash management, will shape the next leg of the story.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations